These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 10780811

  • 1. SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine.
    Masserano JM, Karoum F, Wyatt RJ.
    Behav Pharmacol; 1999 Jul; 10(4):429-32. PubMed ID: 10780811
    [Abstract] [Full Text] [Related]

  • 2. The CB1 cannabinoid receptor antagonist SR 141716A affects A9 dopamine neuronal activity in the rat.
    Gueudet C, Santucci V, Rinaldi-Carmona M, Soubrié P, Le Fur G.
    Neuroreport; 1995 Jul 10; 6(10):1421-5. PubMed ID: 7488739
    [Abstract] [Full Text] [Related]

  • 3. Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioural output of acute D-amphetamine.
    Polissidis A, Chouliara O, Galanopoulos A, Naxakis G, Papahatjis D, Papadopoulou-Daifoti Z, Antoniou K.
    Behav Brain Res; 2014 Aug 15; 270():261-9. PubMed ID: 24867330
    [Abstract] [Full Text] [Related]

  • 4. SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study.
    Bass CE, Griffin G, Grier M, Mahadevan A, Razdan RK, Martin BR.
    Pharmacol Biochem Behav; 2002 Dec 15; 74(1):31-40. PubMed ID: 12376150
    [Abstract] [Full Text] [Related]

  • 5. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
    Janoyan JJ, Crim JL, Darmani NA.
    Pharmacol Biochem Behav; 2002 Dec 15; 71(1-2):155-62. PubMed ID: 11812518
    [Abstract] [Full Text] [Related]

  • 6. SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats.
    Costa B, Vailati S, Colleoni M.
    Behav Pharmacol; 1999 May 15; 10(3):327-31. PubMed ID: 10780247
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of amphetamine- and apomorphine-induced behavioural effects by neuropeptide Y Y(1) receptor antagonist BIBO 3304.
    Kask A, Harro J.
    Neuropharmacology; 2000 Apr 27; 39(7):1292-302. PubMed ID: 10760371
    [Abstract] [Full Text] [Related]

  • 9. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat.
    Martin RS, Secchi RL, Sung E, Lemaire M, Bonhaus DW, Hedley LR, Lowe DA.
    Psychopharmacology (Berl); 2003 Jan 27; 165(2):128-35. PubMed ID: 12404071
    [Abstract] [Full Text] [Related]

  • 10. Potentiation of penile erection and yawning responses to apomorphine by cannabinoid receptor antagonist in rats.
    da Silva GE, Fernandes MS, Takahashi RN.
    Neurosci Lett; 2003 Sep 25; 349(1):49-52. PubMed ID: 12946584
    [Abstract] [Full Text] [Related]

  • 11. Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils.
    Poncelet M, Barnouin MC, Brelière JC, Le Fur G, Soubrié P.
    Psychopharmacology (Berl); 1999 May 25; 144(2):144-50. PubMed ID: 10394995
    [Abstract] [Full Text] [Related]

  • 12. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
    Darmani NA.
    Neuropsychopharmacology; 2001 Feb 25; 24(2):198-203. PubMed ID: 11120402
    [Abstract] [Full Text] [Related]

  • 13. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat.
    Navarro M, Hernández E, Muñoz RM, del Arco I, Villanúa MA, Carrera MR, Rodríguez de Fonseca F.
    Neuroreport; 1997 Jan 20; 8(2):491-6. PubMed ID: 9080435
    [Abstract] [Full Text] [Related]

  • 14. Analogs of SR-141716A (Rimonabant) alter d-amphetamine-evoked [3H] dopamine overflow from preloaded striatal slices and amphetamine-induced hyperactivity.
    Miller DK, Rodvelt KR, Constales C, Putnam WC.
    Life Sci; 2007 Jun 13; 81(1):63-71. PubMed ID: 17532007
    [Abstract] [Full Text] [Related]

  • 15. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats.
    Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR.
    J Pharmacol Exp Ther; 2003 Jul 13; 306(1):93-102. PubMed ID: 12660305
    [Abstract] [Full Text] [Related]

  • 16. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
    Darmani NA.
    Pharmacol Biochem Behav; 2001 Jul 13; 69(1-2):239-49. PubMed ID: 11420092
    [Abstract] [Full Text] [Related]

  • 17. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.
    Rinaldi-Carmona M, Pialot F, Congy C, Redon E, Barth F, Bachy A, Brelière JC, Soubrié P, Le Fur G.
    Life Sci; 1996 Jul 13; 58(15):1239-47. PubMed ID: 8614277
    [Abstract] [Full Text] [Related]

  • 18. Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited.
    Järbe TU, Andrzejewski ME, DiPatrizio NV.
    Pharmacol Biochem Behav; 2002 Nov 13; 73(4):911-9. PubMed ID: 12213538
    [Abstract] [Full Text] [Related]

  • 19. WIN-55,212-2 and SR-141716A alter nicotine-induced changes in locomotor activity, but do not alter nicotine-evoked [3H]dopamine release.
    Rodvelt KR, Bumgarner DM, Putnam WC, Miller DK.
    Life Sci; 2007 Jan 02; 80(4):337-44. PubMed ID: 17067637
    [Abstract] [Full Text] [Related]

  • 20. Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis.
    Santucci V, Storme JJ, Soubrié P, Le Fur G.
    Life Sci; 1996 Jan 02; 58(6):PL103-10. PubMed ID: 8569415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.